3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
15
Endometrial Neoplasms
11
Carcinoma, Non-Small-Cell Lung
10
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Rectal Neoplasms
4
Ovarian Neoplasms
4
Head and Neck Neoplasms
4
Pancreatic Neoplasms
3
Melanoma
3
Colonic Neoplasms
3
Triple Negative Breast Neoplasms
2
Stomach Neoplasms
2
Osteosarcoma
2
Locally Advanced Rectal Cancer (LARC)
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Neuroendocrine
2
Carcinoma, Hepatocellular
2
Carcinoma
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma
1
Recurrence
1
Interventions
Cisplatin
15
Pemetrexed
12
pembrolizumab
9
Carboplatin
8
Nivolumab
7
Cyclophosphamide
6
Platinum
5
Ipilimumab
5
1,2-diaminocyclohexaneplatinum II citrate
5
fludarabine
3
Radiotherapy, Intensity-Modulated
3
Interleukin-2
3
Gemcitabine
3
tremelimumab
2
durvalumab
2
atezolizumab
2
aldesleukin
2
Radiotherapy
2
Radiation
2
Photochemotherapy
2
Pharmaceutical Preparations
2
Methotrexate
2
Drug Therapy
2
Chemotherapy, Adjuvant
2
Cerebral Decortication
2
nintedanib
1
methoxyamine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
cediranib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
dostarlimab
×
1 year
×
Clear all
No trials found.